Amgen's earnings call highlighted continued strong performance, with revenue growth and EPS increases.  Management expressed confidence in 2012's growth prospects, driven by existing franchises and recent launches like Prolia and XGEVA.  However, the call also revealed some uncertainty surrounding EPOGEN due to label and reimbursement changes, suggesting potential short-term volatility in that particular segment.
[1]
